Literature DB >> 15542894

Hormone replacement in women with breast cancer: the HABITS study.

M Brincat1, Y Muscat Baron, E Ciantar.   

Abstract

Ever since Professor William T. Creasman suggested the use of hormone replacement therapy in breast cancer survivors in the early 1980s, interest in this field has been guarded but present. Prescribing HRT to breast cancer survivors was initially thought of as being outrageous. Yet even then with experience in HRT spanning a good three decades, and with the breast cancer epidemic, so confidently predicted, then as it is now never actually materializing, doctors working in the field had started to question the conventional wisdom. The debate on whether to treat breast cancer survivors with HRT has been revisited from time to time as there has been a powerful demand for a solution for such symptomatic women. The HABITS study was thus designed to investigate the use of HRT in breast cancer survivors.

Entities:  

Mesh:

Year:  2004        PMID: 15542894     DOI: 10.1385/endo:24:3:255

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  12 in total

1.  Guidelines for the hormone treatment of women in the menopausal transition and beyond.

Authors:  F Naftolin; H P G Schneider; D W Sturdee
Journal:  Climacteric       Date:  2004-03       Impact factor: 3.005

2.  Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies.

Authors:  G A Colditz; K M Egan; M J Stampfer
Journal:  Am J Obstet Gynecol       Date:  1993-05       Impact factor: 8.661

3.  An experience with estrogen replacement therapy in breast cancer survivors.

Authors:  W R Brewster; P J DiSaia; E A Grosen; K F McGonigle; J L Kuykendall; W T Creasman
Journal:  Int J Fertil Womens Med       Date:  1999 Jun-Aug

4.  Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk.

Authors:  Tove Rylander-Rudqvist; Sara Wedren; Fredrik Granath; Keith Humphreys; Susanne Ahlberg; Elisabete Weiderpass; Mikael Oscarson; Magnus Ingelman-Sundberg; Ingemar Persson
Journal:  Carcinogenesis       Date:  2003-07-04       Impact factor: 4.944

5.  Effect of 17-beta-estradiol on doxorubicin cytotoxicity in human breast cancer cell culture.

Authors:  S Toma; F Leonessa; T Coialbu; G Nicolo; R Rosso
Journal:  Anticancer Res       Date:  1989 Mar-Apr       Impact factor: 2.480

Review 6.  Hormone therapy following breast and uterine cancer.

Authors:  B G Wren
Journal:  Baillieres Clin Endocrinol Metab       Date:  1993-01

7.  Menopause after breast cancer: a survey on breast cancer survivors.

Authors:  Nicoletta Biglia; Marilena Cozzarella; Franca Cacciari; Riccardo Ponzone; Riccardo Roagna; Furio Maggiorotto; Piero Sismondi
Journal:  Maturitas       Date:  2003-05-30       Impact factor: 4.342

8.  Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.

Authors:  J E Dew; B G Wren; J A Eden
Journal:  Climacteric       Date:  2002-06       Impact factor: 3.005

9.  Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality.

Authors:  Eva M Durna; Barry G Wren; Gillian Z Heller; Leo R Leader; Peter Sjoblom; John A Eden
Journal:  Med J Aust       Date:  2002-10-07       Impact factor: 7.738

10.  HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped.

Authors:  L Holmberg; H Anderson
Journal:  Lancet       Date:  2004-02-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.